{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.209","value":"0.1"},{"groupId":"OG001","spread":"1.886","value":"4.157"}]}],"title":"Day -7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.199","value":"0.075"},{"groupId":"OG001","spread":"1.752","value":"3.419"}]}],"title":"Day -6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.24","value":"0.086"},{"groupId":"OG001","spread":"1.437","value":"2.967"}]}],"title":"Day -5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.324","value":"0.1"},{"groupId":"OG001","spread":"1.249","value":"2.579"}]}],"title":"Day -4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.2","value":"0.067"},{"groupId":"OG001","spread":"1.21","value":"2.358"}]}],"title":"Day -3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"0.081"},{"groupId":"OG001","spread":"1.097","value":"1.867"}]}],"title":"Day -2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.611","value":"0.438"},{"groupId":"OG001","spread":"0.931","value":"1.71"}]}],"title":"Day -1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.887","value":"0.938"},{"groupId":"OG001","spread":"1.012","value":"2.163"}]}],"title":"Day 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.205","value":"1.624"},{"groupId":"OG001","spread":"1.056","value":"2.671"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.37","value":"2.076"},{"groupId":"OG001","spread":"0.985","value":"2.778"}]}],"title":"Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.303","value":"2.271"},{"groupId":"OG001","spread":"1.028","value":"2.805"}]}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.454","value":"2.548"},{"groupId":"OG001","spread":"1.161","value":"2.758"}]}],"title":"Day 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.729","value":"2.595"},{"groupId":"OG001","spread":"1.318","value":"2.579"}]}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.665","value":"2.705"},{"groupId":"OG001","spread":"1.33","value":"2.653"}]}],"title":"Day 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Blood was collected and analyzed at a laboratory for serum uric acid levels reported in milligrams(mg)/deciliter(dL). Data is presented for those participants who experienced Grade II to IV aGVHD and those participants who did not experience Grade II to IV aGVHD at pre-transplant and post-transplant.","dispersionType":"Standard Deviation","groups":[{"description":"Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.","id":"OG000","title":"Rasburicase Group"},{"description":"Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.","id":"OG001","title":"Control Group"}],"paramType":"MEAN","populationDescription":"Intent-to-treat population with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Pre-transplant Day -7 to Day -1 and Post-transplant Day 0 to Day 6","title":"Uric Acid Levels","type":"SECONDARY","unitOfMeasure":"mg/dL"}